There is no doubt that India is a coming force in biotechnology -- not only in biosimilars and generics - but in contract research and manufacturing as well.
Here we have a post in PharmaTech Talk written by Kiran Mazumdar Shaw, Chairman of BioCon, one of India's leading biotechnology entrants. She notes that India has long strived to be recognized on the world's biotech stage -- and now it is here. Shaw can lend that historic perspective.
She sees the big opportunity that biosimilars afford India biotech where it can grab a competitive advantage by streamlining an approval process that will be both rigorous and timely. Shaw further notes that because India long lacked capital to fund drug discovery, it developed on a service model. Now that model is well positioned to become a major player on the world stage as MNCs look to outsource -- and many Indian firms present themselves to be strong development partners.
India is on its way to being a global destination for biotechnology.